{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:25:10Z","timestamp":1787505910808,"version":"build-2736575974"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Michael Smith Health Research","award":["BC Trainee Award RT-2020-0493"],"award-info":[{"award-number":["BC Trainee Award RT-2020-0493"]}]},{"name":"Michael Smith Health Research","award":["BC Trainee Award RT-2020-0493"],"award-info":[{"award-number":["BC Trainee Award RT-2020-0493"]}]}],"content-domain":{"domain":["www.atsjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,1]]},"DOI":"10.1513\/annalsats.202405-451rl","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T10:01:46Z","timestamp":1730368906000},"page":"302-305","update-policy":"https:\/\/doi.org\/10.1164\/crossmarkpolicies","source":"Crossref","is-referenced-by-count":1,"title":["Reduction in 3-Year Risk of Death or Lung Transplant for Individuals with Advanced Cystic Fibrosis Lung Disease Treated with Elexacaftor\/Tezacaftor\/Ivacaftor"],"prefix":"10.1093","volume":"22","author":[{"given":"Allison J.","family":"Love","sequence":"first","affiliation":[{"name":"St. Paul\u2019s Hospital Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9671-9383","authenticated-orcid":false,"given":"Sameer","family":"Desai","sequence":"additional","affiliation":[{"name":"University of British Columbia Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie Y.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Cystic Fibrosis Canada Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Stephenson","sequence":"additional","affiliation":[{"name":"Unity Health Toronto Toronto, Ontario, Canada"},{"name":"University of Toronto Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Stanojevic","sequence":"additional","affiliation":[{"name":"Dalhousie University Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4241-8718","authenticated-orcid":false,"given":"Alessandro N.","family":"Franciosi","sequence":"additional","affiliation":[{"name":"St. Paul\u2019s Hospital Vancouver, British Columbia, Canada"},{"name":"University of British Columbia Vancouver, British Columbia, Canada"},{"name":"University College Dublin Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley S.","family":"Quon","sequence":"additional","affiliation":[{"name":"St. Paul\u2019s Hospital Vancouver, British Columbia, Canada"},{"name":"University of British Columbia Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"2026012203075373900_bib1","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1513\/AnnalsATS.202312-1065OC","article-title":"Multisystemic effects of elexacaftor-tezacaftor-ivacaftor in adults with cystic fibrosis and advanced lung disease","volume":"21","author":"Burgel","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026012203075373900_bib2","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012203075373900_bib3","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2026012203075373900_bib4","doi-asserted-by":"crossref","first-page":"2003079","DOI":"10.1183\/13993003.03079-2020","article-title":"Efficacy of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"57","author":"O\u2019Shea","year":"2021","journal-title":"Eur Respir J"},{"key":"2026012203075373900_bib5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026012203075373900_bib6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.chest.2021.08.073","article-title":"Ethical dilemma: elexacaftor-tezacaftor-ivacaftor or lung transplantation in cystic fibrosis and end-stage lung disease?","volume":"161","author":"Breuer","year":"2022","journal-title":"Chest"},{"key":"2026012203075373900_bib7","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jcf.2017.03.004","article-title":"A 3-year prognostic score for adults with cystic fibrosis","volume":"16","author":"Nkam","year":"2017","journal-title":"J Cyst Fibros"},{"key":"2026012203075373900_bib8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jcf.2018.10.014","article-title":"Validation of the French 3-year prognostic score using the Canadian Cystic Fibrosis Registry","volume":"18","author":"Coriati","year":"2019","journal-title":"J Cyst Fibros"},{"key":"2026012203075373900_bib9","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jcf.2021.08.008","article-title":"Validation of the French 3-year prognostic score for death or lung transplant in the United States cystic fibrosis population","volume":"21","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"}],"container-title":["Annals of the American Thoracic Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/2\/302\/66008202\/annalsats_22_2_302.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/annalsats\/article-pdf\/22\/2\/302\/66008202\/annalsats_22_2_302.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:08:08Z","timestamp":1769069288000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/annalsats\/article\/22\/2\/302\/8380586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":9,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,1]]},"published-print":{"date-parts":[[2025,2,1]]}},"URL":"https:\/\/doi.org\/10.1513\/annalsats.202405-451rl","relation":{},"ISSN":["2329-6933","2325-6621"],"issn-type":[{"value":"2329-6933","type":"print"},{"value":"2325-6621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"2025-01-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}